Abstract

Aim: To investigate proline-rich protein 11 (PRR11) transcription levels and its prognostic effect in early-stage (non-metastatic) bladder cancer.

Materials and Methods: Thirty-one patients diagnosed with early-stage (non-metastatic) bladder cancer were included in the study. The patients' tumor tissues at diagnosis were obtained from the pathology laboratory, PRR11 transcription levels were analyzed, and "median fold change" values for PRR11 transcription levels were obtained. According to the median PRR11 transcription level determined in these values, the patients were divided into two groups (n=16 and n=15). The demographic and clinicopathological characteristics of the patients were examined, and the survival outcomes of the two groups were compared.

Results: The determined median PRR11 transcription level was 1.386 (range: 0.135- 2.016). In the patient group with a median PRR11 transcription level ≤1.381 (n=16), median disease-free survival (mDFS) was 19 months (95% CI: 2.1-48.4 months); in the group with >1.381 (n=15), mDFS was 11 months (95% CI: 7.5-14.4 months). In the group with ≤1.381, median overall survival (mOS) was 27 months (95% CI: 4.1-58.3 months), and in the group with >1.381, mOS was 14 months (95% CI: 8.1-19.8 months).

Conclusion: Our study found a negative correlation between PRR11 transcription level and survival outcomes in early-stage bladder cancer. PRR11 transcription level may be a prognostic marker in early-stage bladder cancer patients. More comprehensive, prospective, and randomized controlled trials are needed.

Key words: Biomarker; bladder cancer; prognosis; proline-rich protein 11